

Patentgesetz [German Patent Act] (1936, revised 1980, amended 2009) (Ger.); translated in World Intellectual Property Organization, Patent Law, http://www.wipo.int/wipolex/en/text.jsp?file_id=238776.

Speeches and Reports

European Commission, *Communication from the Commission – Executive Summary of the Pharmaceutical Sector Inquiry Report*, (July 8, 2011) available at http://ec.europa.eu/competition/sectors/pharmaceuticals/inquiry/staff_working_paper_part1.pdf.

Institute for Quality and Efficiency in Health Care, IQWiG Reports – Commission No. A11-24 Cabazitaxel – Benefit assessment according to § 35a Social Code Book V, (Jan. 12, 2012), available at https://www.iqwig.de/download/A11-24_Extract_Cabazitaxel_Benefit_assessment_35a_Social_Code_Book_V.pdf.

Sir R. Jacob, *Patents and Pharmaceuticals – a speech given on 28th November 2008 at the presentation of the Directorate-General of Competition's Preliminary Report of the Pharma-sector inquiry*, available at <http://ec.europa.eu/competition/sectors/pharmaceuticals/inquiry/jacob.pdf>.

Press release

Press release, AGCM, Drugs: Pfizer sanctioned with 10.6 million Euro fine for abuse of a dominant position (Jan. 17, 2012).

Press release Novagali Pharma, Catioprost Phase II positive results (Sept. 8, 2011).

Press release, QLT inc., (Aug. 29, 2011).

Press release, Sanofi, 2011 Results Benefit from Genzyme Acquisition Net Sales and Business EPS1 up 9.2%2 in Q4 (Feb. 8, 2012).

Others

M. Dickson, J.P. Gagnon, The Cost of New Drug Discovery and Development, available at: <http://www.discoverymedicine.com/Michael-Dickson/2009/06/20/the-cost-of-new-drug-discovery-and-development/>.

Angelo DePalma, *Patent expiration: Innovate or die*, Eyeforpharma, Feb. 3, 2011, available at <http://social.eyeforpharma.com/>.

European Federation of Pharmaceutical Industries and Associations: The Pharmaceutical Industry in Figures, 2012 Edition, available at: http://www.efpia.eu/sites/www.efpia.eu/files/EFPIA_Figures_2012_Final-20120622-003-EN-v 1.pdf.

List of works cited

- EMA, *Guideline on the Investigation of Drug Interaction*, (Apr. 22, 2010) http://www.emea.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/05/WC500090112.pdf.
- EMA, *EMA procedural advice for users of the centralised procedure for generic/ hybrid applications*, available at http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2009/10/WC500004018.pdf.
- GlaxoSmithKline Briefings, *Evergreening*, (March, 2007), available at <http://www.gsk.com/policies/GSK-and-evergreening.pdf>.
- Merck Manuals, <http://www.merckmanuals.com/home/sec15/ch182/ch182h.html>.
- The Thomson Corporation, News & Highlights from week 39, Curr. Pat. Gaz., Sept. 26 2008.
- Union of European practitioners in intellectual property – Biotechnology Commission, *Brief report on the so called “Bolar” Exemption* Annex of Newsletter (May 1, 2009), found at <http://www.union-ip.org/union/WebObjects/union.woa#vieweditmember>.
- John Zhikong He, *Docetaxel*, IP Front Line, <http://www.ipfrontline.com/depts/article.aspx?id=24725&deptid=5>.